Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
07
Today In Oncology
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer
Can Nicotinamide Lessen the Risk of Skin Cancer Development
More Tattoos, Lessened Risk of Melanoma? New Study Investigates
Patient-Reported Outcomes and Overall Survival in Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo